Zepbound vs. CPAP for Sleep Apnea: What SURMOUNT-OSA Really Means
As of October 2026, Zepbound is the only medication FDA-approved to treat obstructive sleep apnea itself, but it is not a straight replacement for your CPAP machine. In the SURMOUNT-OSA trials, it cut breathing interruptions roughly in half over a year, and up to about half of patients reached a level where CPAP might no longer be recommended. The American Academy of Sleep Medicine positions Zepbound as an add-on to CPAP, not a substitute, so the realistic question is whether it can help you need your machine less.
Key takeaways
- The FDA approved Zepbound (tirzepatide) on December 20, 2024, for moderate to severe obstructive sleep apnea in adults with obesity.
- In SURMOUNT-OSA, Zepbound lowered the apnea-hypopnea index (AHI) by about 25 to 29 events per hour at 52 weeks, versus about 5 with placebo.
- About 42% to 50% of people on Zepbound reached remission or mild, symptom-free sleep apnea, versus 14% to 16% on placebo.
- CPAP works the night you use it, but only if you use it. Zepbound takes months to work and its benefit likely fades if you stop.
- Do not stop CPAP on your own. Sleep specialists recommend a repeat sleep study once your weight stabilizes.
How they work: a different job for each
CPAP (continuous positive airway pressure) blows pressurized air through a mask to hold your airway open while you sleep. It treats the mechanical problem directly, every night you wear it. The American Academy of Sleep Medicine's PAP treatment guideline gives a strong recommendation for positive airway pressure over no therapy in adults with excessive sleepiness from sleep apnea.
Zepbound is a once-weekly injection that activates GIP and GLP-1 hormone receptors, reducing appetite and body weight. Less fat around the neck and upper airway can mean fewer collapses during sleep. Its OSA indication covers adults with moderate to severe OSA and obesity, used with a reduced-calorie diet and more physical activity, per the Zepbound prescribing information. The AASM's 2026 provider fact sheet lists eligibility as a BMI of 30 or higher and an AHI of 15 or more events per hour.
What SURMOUNT-OSA actually tested
SURMOUNT-OSA was two 52-week, placebo-controlled trials with 469 adults who had obesity and moderate to severe sleep apnea, according to Drug Topics. Study 1 enrolled people who could not or would not use PAP. Study 2 enrolled people already using PAP who planned to keep using it.
One detail matters for CPAP users: in Study 2, participants stopped PAP for 7 days before each sleep study, according to Lilly's medical summary. So the results show how much the drug improved breathing with the machine off, not how Zepbound plus CPAP compares with CPAP alone.
| Week 52 result | Study 1: not on PAP | Study 2: on PAP (tested off PAP) |
|---|---|---|
| Participants | 234 | 235 |
| Starting AHI (events/hour) | 51.5 | 49.5 |
| AHI change, Zepbound vs. placebo | -25.3 vs. -5.3 | -29.3 vs. -5.5 |
| Percent AHI change, Zepbound vs. placebo | -50.7% vs. -3.0% | -58.7% vs. -2.5% |
| At least 50% AHI reduction | 61% vs. 19% | 72% vs. 23% |
| Remission or mild, symptom-free OSA | 42% vs. 16% | 50% vs. 14% |
| Body weight change | About 18% loss with Zepbound vs. about 2% with placebo | About 20% loss with Zepbound vs. about 2% with placebo |
Source: AASM Zepbound provider fact sheet (2026); participant and baseline figures from Drug Topics.
Beyond AHI, Zepbound reduced a measure of oxygen-deprivation burden by 61% to 70% more than placebo and lowered systolic blood pressure, per the American College of Cardiology trial summary. The ACC also notes limits: the trials did not require daytime sleepiness symptoms at entry, and the long-term cardiovascular impact of these changes is not yet known.
What "remission" means here
The trials counted someone as reaching the target if their AHI dropped below 5, or to 5 to 14 with an Epworth Sleepiness Scale score of 10 or less. At those levels, the investigators wrote that CPAP "may not be recommended," as reported by MDedge. That is not the same as patients actually giving up their machines, which the trials did not measure.
Exploring Zepbound for sleep apnea?
Compare current tirzepatide options and pricing before you talk with your sleep doctor.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Zepbound vs. CPAP head to head
No trial has compared Zepbound directly with CPAP, and the AASM fact sheet says so plainly. What we can compare is how each one works in practice.
| Factor | CPAP | Zepbound |
|---|---|---|
| How it works | Air pressure holds the airway open | Weight loss reduces airway collapse |
| Speed | Works the first night it is used | Gradual; doses step up every 4 weeks and trials measured at 52 weeks |
| Main challenge | Nightly adherence and mask comfort | GI side effects, weekly injections, ongoing cost |
| If you stop | Apnea returns that night | Weight regain is expected, so benefit likely fades |
| Other effects | Treats breathing during sleep only | Weight, blood pressure, and blood sugar effects |
| Guideline role | Standard first-line therapy | Add-on to comprehensive OSA care, not a replacement |
Sources: AASM PAP guideline; AASM Zepbound fact sheet.
CPAP's real weakness: actually using it
CPAP only helps on nights you wear it. A 20-year review of 82 studies found an average nonadherence rate of about 34%, measured against a 7-hour night, according to Rotenberg and colleagues in the Journal of Otolaryngology. Medicare ties ongoing coverage to use: during the first three months, patients must use the device at least 4 hours a night on 70% of nights in a consecutive 30-day window, per CGS Medicare's PAP coverage guide.
This is where Zepbound can matter most. Study 1 was built for people who could not or would not use PAP, and that group still saw their AHI fall by about half.
Zepbound's real weakness: side effects and staying on it
Across SURMOUNT-OSA, diarrhea affected 24% of people on Zepbound versus 11% on placebo, and nausea 24% versus 8%, per the ACC summary. Acute pancreatitis occurred in 0.9% of those on the drug versus none on placebo. The AASM fact sheet says patients will regain weight if they stop the medication, so a long-term plan is needed to keep the sleep apnea benefit.
Cost and coverage
Medicare covers CPAP when the adherence rules above are met. Zepbound coverage varies more. Medicare drug plans can cover GLP-1s for obstructive sleep apnea under standard Part D, and people who already qualify that way are generally excluded from Medicare's separate GLP-1 Bridge weight-loss program, according to WTOP's July 2026 explainer.
Without coverage, Zepbound self-pay prices are $299 per month at 2.5 mg, $399 at 5 mg, and $449 for 7.5 mg through 15 mg, for vials or the KwikPen. Lilly set those vial prices in a December 2025 price cut reported by BioSpace. Its savings page lists the same KwikPen tiers, notes that the $449 KwikPen price requires a refill within 45 days, and says the current self-pay card ends December 31, 2026. Check current pricing before you decide, since it has changed several times.
Who might lean which way
- You use CPAP well and feel rested: CPAP is already doing its job. Zepbound may still make sense for weight or metabolic reasons, and the AASM says PAP needs should be reassessed as weight comes off, but there is no urgency to switch.
- You cannot tolerate CPAP: This is the group SURMOUNT-OSA Study 1 tested. Zepbound gives you a proven option, ideally alongside other therapies such as an oral appliance.
- You have obesity and other conditions like high blood pressure or prediabetes: Zepbound's broader effects may add value, though the long-term heart benefit in sleep apnea is still being studied.
- Your BMI is under 30 or your OSA is mild: You fall outside the approved OSA indication, so CPAP or other standard treatments remain the main path.
The verdict
CPAP remains the first-line treatment for obstructive sleep apnea because it works immediately and reliably when used. Zepbound is a strong second tool for adults with obesity: in SURMOUNT-OSA it roughly halved breathing interruptions and brought up to half of patients to a level where CPAP might not be recommended. Treat it as a way to need your machine less, not as permission to put it in the closet. If you start Zepbound, keep using CPAP and ask for a repeat sleep study once your weight has stabilized, as the AASM advises. If you cannot tolerate CPAP at all, Zepbound is the best-studied alternative to discuss with your sleep specialist.
See what Zepbound would cost you
Compare providers' current self-pay and insurance pricing for tirzepatide.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Can Zepbound replace a CPAP machine?
Not automatically. The American Academy of Sleep Medicine positions Zepbound as an add-on to comprehensive sleep apnea care, not a replacement for PAP, and advises reassessing PAP needs as weight comes off.
How much did Zepbound improve sleep apnea in trials?
In SURMOUNT-OSA, Zepbound lowered the apnea-hypopnea index by about 25 to 29 events per hour at 52 weeks versus about 5 with placebo, roughly a 51% to 59% reduction.
Who is Zepbound approved for in sleep apnea?
Adults with moderate to severe obstructive sleep apnea and obesity. The AASM lists eligibility as a BMI of 30 or higher and an AHI of 15 or more events per hour.
Should I get a new sleep study on Zepbound?
The AASM suggests considering a repeat home sleep test or in-lab study once your weight has stabilized at its lowest point. Do not stop CPAP without that reassessment.
Does Medicare cover Zepbound for sleep apnea?
Medicare drug plans can cover GLP-1s for obstructive sleep apnea under standard Part D. Coverage details vary by plan, so check with yours.
Sources
- Drug Topics: FDA approves tirzepatide for obstructive sleep apnea in patients with obesity
- Zepbound (tirzepatide) prescribing information
- American Academy of Sleep Medicine: Zepbound provider fact sheet (2026)
- American Academy of Sleep Medicine: PAP treatment guideline at a glance
- Lilly Medical: SURMOUNT-OSA Study 2 (on PAP therapy)
- American College of Cardiology: SURMOUNT-OSA trial summary
- MDedge: Tirzepatide reduces sleep interruptions in SURMOUNT-OSA
- Rotenberg et al.: Trends in CPAP adherence over twenty years of data collection
- CGS Medicare: PAP device coverage requirements
- WTOP: Does Medicare cover GLP-1 weight loss drugs like Ozempic and Zepbound?
- BioSpace: Lilly cuts Zepbound prices again in its direct-to-consumer program
- Eli Lilly: Zepbound coverage and savings
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.